Unexpected toxicity and safety issues constitute one of the most disruptive events in drug R&D, with one third of drug attrition still directly related to these events. In this context, a translational approach to drug safety and prompt access to actionable safety intelligence can significantly reduce patient burden and avoid costly failures.
Since 2017, the OFF-XTM portal has been supporting translational researchers in pharmaceutical and healthcare organizations to de-risk drug R&D programs.
Rapid access to actionable safety intelligence via OFF-X provides a critical competitive advantage for your R&D:
- Time saving: OFF-X reduces the time and resources required to retrieve critical safety intelligence. OFF-X breaks information silos by comprehensively integrating disparate sources of data with a fast turnaround.
- Comprehensiveness: OFF-X’s extensive coverage of information sources provides daily access to key data that is not readily available and that may not be published elsewhere after a first mention, for example a reference in a scientific congress.
- OFF-X covers all phases of drug R&D, including first-in-class and emerging targets.
- OFF-X provides a unique translational approach: used across a wide range of departments and facilitates the translational safety intelligence paradigm by interconnecting and integrating critical safety intelligence form early target discovery to post-marketing and patient safety.
Contact us today to arrange a demonstration and request a 2 week trial